????
Conditions
Interventions
Tolvaptan group:tolvaptan 15mg, once daily, for 3 days
Control group:spironolactone 100mg, furosemide 40mg, once daily, for 3 days
Sponsors
Tianjin First Centre Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients aged 18-65 years; 2. Primary carcinoma of liver edema patients after undergoing partial hepatectomy; 3. Patients are with?hyponatremia after surgery within 48hours, the definition of hyponatremia is serum sodium level 25; 6. Patients are able to understand the purpose of the study and can sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Meet specification of tolvaptan contraindications 2. Patients with the following diseases, comorbidities or symptoms: Acute /chronic aortic dissection patients; active myocarditis or amyloid cardiomyopathy; suspected circulating blood volume reduction, obstructive hypertrophic cardiomyopathy, poorly controlled diabetes, fasting glucose higher than 220 mg/dl (or 12.21 mmol/l); dysuria urethral stricture, calculus and tumor induced by; 3. Patients with shock and persistent bacterial infection before surgery; 4. Patients with hypoalbuminemia; 5. Patients with hepatic encephalopathy or hepatorenal syndrome; 6. Patients with gastrointestinal bleeding history within 10 days and doctors diagnose the patients with gastrointestinal bleeding risk; 7. Pregnancy test positive patients; 8. Abuse of alcohol or drugs or patients who are participating in other clinical trials; 9. The investigators consider that patients are not suitable to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| abdominal circumference;B-ultrasound;drainage tube extubation time;body weight; | — |
Countries
China
Contacts
Public ContactZhang Yamin
Tianjin First Centre Hospital
Outcome results
None listed